News

Geron Corporation (GERN) Q3 2024 Earnings Call Transcript

1 Mins read

Geron Corporation (NASDAQ:GERN) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET

Company Participants

Aron Feingold – Vice President of IR and Corporate Communication
John Scarlett – Chairman and CEO
Jim Ziegler – EVP and CCO
Michelle Robertson – EVP and CFO
Faye Feller – EVP, CMO
Andrew Grethlein – EVP, COO

Conference Call Participants

Tara Bancroft – T. D. Cowen
Faisal Khurshid – Leerink Partners
Corinne Johnson – Goldman Sachs
Carter Gould – Barclays
Emily Bodnar – H.C. Wainwright
Stephen Willey – Stifel
Kalpit Patel – B. Riley Securities
Gil Blum – Needham & Company

Operator

Hello, and welcome to the Geron Corporation Third Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions].

I would now like to turn the conference over to Aron Feingold, Vice President of Investor Relations and Corporate Communication. You may begin.

Aron Feingold

Good morning, everyone. Welcome to the Geron Corporation third quarter 2024 earnings conference call. I am Aron Feingold, Geron’s Vice President of Investor Relations and Corporate Communication.

I’m joined today by several members of Geron’s management team. Dr. John Scarlett, Chairman and Chief Executive Officer; Michelle Robertson, Executive Vice President and Chief Financial Officer; Jim Ziegler, Executive Vice President and Chief Commercial Officer; Dr. Faye Feller, Executive Vice President, Chief Medical Officer; and Dr. Andrew Grethlein, Executive Vice President, Chief Operating Officer.

Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections, including those relating to the launch, commercial opportunity and therapeutic potential of RYTELO, anticipated clinical and commercial events and related timelines, the sufficiency of Geron’s financial resources and other statements that are not historical facts.

Read the full article here

Related posts
News

'May Cut' Isn't 'Will Cut', Expect More Volatility Ahead (NDX)

1 Mins read
This article was written by Follow David H. Lerner is an analyst with a decade of experience utilizing his professional background in…
News

FFLC: Measured Exposure For Growth With Valuation Discipline (BATS:FFLC)

1 Mins read
This article was written by Follow I am an individual investor. My main focus on investing is to achieve capital appreciation by…
News

Allspring Special Small Cap Value Fund Q2 2025 Commentary (ESPAX)

1 Mins read
This article was written by Follow Allspring is a company committed to thoughtful investing, purposeful planning, and the desire to elevate investing…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *